← Leaderboards
A Thomas Look
Dana-Farber Cancer Institute
$30,189,128
Attributed
$31,705,619
Total exposure
18
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$51,342,165 · 19
By mechanism
P01$27,442,279 · 9
R01$15,479,480 · 7
R35$7,272,766 · 1
P30$1,147,640 · 2
Top collaborators
- John M Maris5 shared
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- M. James You$1,266,604
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularMalignant NeoplasmsPhenotypePathway InteractionsProgramsCellsZebrafishGenesProteinsBaseMalignant - DescriptorOncogenicPathogenesisGeneticMutationAnimal ModelMediatingPharmaceutical PreparationsT-LymphocyteOncogenesLeukemiaTranscription FactorApoptosisGene Targeting
Grant awards (94)
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer$1,025,513
R35 · FY2022 · CA · contact PI
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer$1,046,441
R35 · FY2021 · CA · contact PI
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer$1,046,441
R35 · FY2020 · CA · contact PI
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer$1,015,048
R35 · FY2019 · CA · contact PI
Role of LMO1 in Neuroblastoma Initiation and Maintenance$588,631
R01 · FY2019 · CA
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer$1,046,441
R35 · FY2018 · CA · contact PI
Role of LMO1 in Neuroblastoma Initiation and Maintenance$606,838
R01 · FY2018 · CA
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer$1,046,441
R35 · FY2017 · CA · contact PI
Role of LMO1 in Neuroblastoma Initiation and Maintenance$606,838
R01 · FY2017 · CA
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer$1,046,441
R35 · FY2016 · CA · contact PI
Role of LMO1 in Neuroblastoma Initiation and Maintenance$606,838
R01 · FY2016 · CA
Leukemia$93,191
P30 · FY2016 · CA · contact PI
Role of LMO1 in Neuroblastoma Initiation and Maintenance$623,838
R01 · FY2015 · CA
Discovery of New Targets and Pathways for T-ALL Therapy$378,989
R01 · FY2015 · CA · contact PI
Leukemia$93,227
P30 · FY2015 · CA · contact PI
Molecular Pathways to Thynmic Lymphoma and Leukemia$1,950,256
P01 · FY2014 · CA · contact PI
Mechanisms of Transformation by TAL1/SCL in Thymic Malignancy$682,792
P01 · FY2014 · CA · contact PI
Discovery of New Targets and Pathways for T-ALL Therapy$367,619
R01 · FY2014 · CA · contact PI
Leukemia$276,222
P30 · FY2014 · CA · contact PI
Administrative Core$54,673
P01 · FY2014 · CA · contact PI
Molecular Pathways to Thynmic Lymphoma and Leukemia$1,895,397
P01 · FY2013 · CA · contact PI
Mechanisms of Transformation by TAL1/SCL in Thymic Malignancy$639,740
P01 · FY2013 · CA · contact PI
Discovery of New Targets and Pathways for T-ALL Therapy$356,250
R01 · FY2013 · CA · contact PI
Leukemia$114,538
P30 · FY2013 · CA · contact PI
Leukemia$85,485
P30 · FY2013 · CA · contact PI
Leukemia$50,000
P30 · FY2013 · CA · contact PI
Administrative Core$47,311
P01 · FY2013 · CA · contact PI
Leukemia$12,500
P30 · FY2013 · CA · contact PI
Molecular Pathways to Thynmic Lymphoma and Leukemia$2,022,365
P01 · FY2012 · CA · contact PI
Mechanisms of Transformation by TAL1/SCL in Thymic Malignancy$683,754
P01 · FY2012 · CA · contact PI
Discovery of New Targets and Pathways for T-ALL Therapy$378,989
R01 · FY2012 · CA · contact PI
Leukemia$93,207
P30 · FY2012 · CA · contact PI
Leukemia$75,000
P30 · FY2012 · CA · contact PI
Administrative Core$50,953
P01 · FY2012 · CA · contact PI
Leukemia$50,000
P30 · FY2012 · CA · contact PI
Molecular Pathways to Thynmic Lymphoma and Leukemia$2,028,518
P01 · FY2011 · CA · contact PI
Mechanisms of Transformation by TAL1/SCL in Thymic Malignancy$687,030
P01 · FY2011 · CA · contact PI
Synthetic Lethal Targeting of p53 in Myelodysplasia$427,500
R01 · FY2011 · HL · contact PI
Administrative Core$51,594
P01 · FY2011 · CA · contact PI
Molecular Pathways to Thynmic Lymphoma and Leukemia$1,988,819
P01 · FY2010 · CA · contact PI
Mechanisms of Transformation by TAL1/SCL in Thymic Malignancy$604,357
P01 · FY2010 · CA · contact PI
Synthetic Lethal Targeting of p53 in Myelodysplasia$427,500
R01 · FY2010 · HL · contact PI
Zebrafish Screens for Genetic Modifiers and Human Application in T-ALL$310,368
P01 · FY2010 · CA · contact PI
Genetic Modifiers of the Anti-apoptotic Functions of Bcl-2$303,525
R01 · FY2010 · CA · contact PI
Administrative Core$53,519
P01 · FY2010 · CA · contact PI
Synthetic Lethal Targeting of p53 in Myelodysplasia$427,500
R01 · FY2009 · HL · contact PI
Genetic Modifiers of the Anti-apoptotic Functions of Bcl-2$389,950
R01 · FY2009 · CA · contact PI
Zebrafish Screens for Genetic Modifiers and Human Application in T-ALL$304,947
P01 · FY2009 · CA · contact PI
Genetic Modifiers of the Anti-apoptotic Functions of Bcl-2$303,525
R01 · FY2009 · CA · contact PI
Molecular Pathways to Thymic Lymphoma and Leukemia$1,974,630
P01 · FY2008 · CA · contact PI
Mechanisms of Transformation by TAL1/SCL in Thymic Malignancy$619,765
P01 · FY2008 · CA · contact PI
Synthetic Lethal Targeting of p53 in Myelodysplasia$427,500
R01 · FY2008 · HL · contact PI
Leukemogenic Slug Pathway in Hematopoietic Cell Survival$405,347
R01 · FY2008 · CA · contact PI
Genetic Modifiers of the Anti-apoptotic Functions of Bcl-2$303,525
R01 · FY2008 · CA · contact PI
Zebrafish Screens for Genetic Modifiers and Human Application in T-ALL$296,757
P01 · FY2008 · CA · contact PI
Molecular Pathways to Thymic Lymphoma and Leukemia$1,958,333
P01 · FY2007 · CA · contact PI
Mechanisms of Transformation by TAL1/SCL in Thymic Malignancy$614,978
P01 · FY2007 · CA · contact PI
Synthetic Lethal Targeting of p53 in Myelodysplasia$427,500
R01 · FY2007 · HL · contact PI
Leukemogenic Slug Pathway in Hematopoietic Cell Survival$405,347
R01 · FY2007 · CA · contact PI
Neuroblastoma Tumor Suppressor Genes in Zebrafish$332,386
R01 · FY2007 · CA · contact PI
Genetic Modifiers of the Anti-apoptotic Functions of Bcl-2$294,723
R01 · FY2007 · CA · contact PI
Zebrafish Screens for Genetic Modifiers and Human Application in T-ALL$294,496
P01 · FY2007 · CA · contact PI
Molecular Pathways to Thymic Lymphoma and Leukemia$1,961,314
P01 · FY2006 · CA · contact PI
Mechanisms/Transformation by TAL1/SCL in Thymic Neoplasm$457,441
P01 · FY2006 · CA · contact PI
Leukemogenic Slug Pathway in Hematopoietic Cell Survival$417,454
R01 · FY2006 · CA · contact PI
Neuroblastoma Tumor Suppressor Genes in Zebrafish$342,313
R01 · FY2006 · CA · contact PI
Genetic Modifiers of the Anti-apoptotic Functions of Bcl-2$302,489
R01 · FY2006 · CA · contact PI
Zebrafish Screens for Genetic Modifiers and Human Application in T-ALL$216,446
P01 · FY2006 · CA · contact PI
Molecular Pathways to Thymic Lymphoma and Leukemia$1,953,240
P01 · FY2005 · CA
Mechanisms/Transformation by TAL1/SCL in Thymic Neoplasm$444,656
P01 · FY2005 · CA
Leukemogenic Slug Pathway in Hematopoietic Cell Survival$427,500
R01 · FY2005 · CA
Genetic Basis of Myeloid Neoplasia--Mutagenesis Screens$413,300
R01 · FY2005 · CA
Neuroblastoma Tumor Suppressor Genes in Zebrafish$350,550
R01 · FY2005 · CA
Molecular Pathways to Thymic Lymphoma and Leukemia$1,903,674
P01 · FY2004 · CA
Mechanisms/Transformation by TAL1/SCL in Thymic Neoplasm$436,345
P01 · FY2004 · CA
Leukemogenic Slug Pathway in Hematopoietic Cell Survival$427,500
R01 · FY2004 · CA
Genetic Basis of Myeloid Neoplasia--Mutagenesis Screens$413,300
R01 · FY2004 · CA
Neuroblastoma Tumor Suppressor Genes in Zebrafish$350,550
R01 · FY2004 · CA
Administrative Core$56,090
P01 · FY2004 · CA
Genetic Basis of Myeloid Neoplasia--Mutagenesis Screens$413,300
R01 · FY2003 · CA
CHIMERIC E2A-HLF TRANSCRIPTION FACTOR IN ACUTE LEUKEMIA$56,245
R01 · FY2003 · CA
CHIMERIC E2A-HLF TRANSCRIPTION FACTOR IN ACUTE LEUKEMIA$460,268
R01 · FY2002 · CA
Genetic Basis of Myeloid Neoplasia--Mutagenesis Screens$413,683
R01 · FY2002 · CA
MOLECULAR PATHOGENESIS--T CELL ACUTE LYMPHOBLASTIC LEUKE$0
P01 · FY2002 · CA
CORE--CYTOGENETICS SHARED RESOURCE$0
P30 · FY2002 · CA
GENETICS OF MYELOID NEOPLASIA--MUTAGENESIS IN ZEBRAFISH$0
P01 · FY2002 · CA
CHIMERIC E2A-HLF TRANSCRIPTION FACTOR IN ACUTE LEUKEMIA$448,487
R01 · FY2001 · CA
Genetic Basis of Myeloid Neoplasia--Mutagenesis Screens$414,833
R01 · FY2001 · CA
CORE--CYTOGENETICS SHARED RESOURCE$0
P30 · FY2001 · CA
MOLECULAR PATHOGENESIS--T CELL ACUTE LYMPHOBLASTIC LEUKE$0
P01 · FY2001 · CA
CHIMERIC E2A-HLF TRANSCRIPTION FACTOR IN ACUTE LEUKEMIA$437,050
R01 · FY2000 · CA
CORE--CYTOGENETICS SHARED RESOURCE$204,270
P30 · FY2000 · CA
CHROMOSOME 1P TUMOR SUPPRESSORS IN NEUROBLASTOMA$197,721
P01 · FY2000 · CA
MOLECULAR PATHOGENESIS--T CELL ACUTE LYMPHOBLASTIC LEUKE$0
P01 · FY2000 · CA